Abstract
Clean sport competition is of significant concern to many governments and sporting organizations. Highly sensitive and rapid sensors are needed to improve the detection of performance enhancing drugs in sports as athletes take diuretics to dilute the concentration of drugs in their urine and microdose under the detectable limits of current sensors. Here we demonstrate, using frequency locked microtoroid optical resonators, a three order of magnitude improvement in detection limit over the current gold standard, mass spectrometry, for the common performance enhancing drug, human chorionic gonadotropin (hCG). hCG, also known as the pregnancy hormone, was detected both in simulated urine and in the urine of pregnant donors at a concentration of 1 and 3 femtomolar, respectively. We anticipate that the sensitivity provided by frequency locked optical microcavities can enable a new standard in anti-doping research.
The use of performance enhancing drugs during athletic events is prohibited by the World Anti-Doping Association (WADA). To monitor the use of these drugs, anti-doping drug tests are routinely performed during athletic events1,2. These tests can detect minute quantities of chemicals from bodily fluids, such as blood or urine. Mass spectrometry is currently the gold standard3,4 for detecting various doping agents; however, it can have insufficient limits of detection5, requires a trained operator, involves specialized enzymes,6,7 and can be expensive, costing in excess of 100 dollars per assay.
In this work we focus on detecting human chorionic gonadotropin (hCG) (Fig. 1a). hCG is a hormone secreted during pregnancy and is one of the most common doping agents8. It is used by athletes to increase the secretion of testosterone and is on the World Anti-Doping Association (WADA)’s list of prohibited substances for male athletes.9 The smallest detectable quantity of hCG by mass spectrometry is approximately 2 pM8, which is only slightly below the current doping threshold of 13 pM that has been imposed by WADA10. Based on the concentration of hCG measured in baseline samples of healthy male urine, it has been recommended to reduce the doping threshold further to ~ 2.4 pM in order to avoid false negative results in doping tests2,5. As mass spectrometry’s limit of detection is very close to this level, it is unlikely that mass spectroscopy would be a robust and reliable method of enforcing this limit.
Because of its implications in pregnancy and doping, there has been much research done in enabling the sensitive and selective detection of hCG from bodily fluids11. The most effective techniques are either electrochemical or optical label-free biosensors.11 Electrochemical sensors measure changes in electrical impedance when hCG binds to the sensor12–19. Although they have high sensitivities and in some cases can detect hCG at a concentration of 30 fM17, electrochemical sensors can have issues with sample reproducibility and sensor stability.20 Optical biosensors measure changes in absorption, refractive index, or light emission caused by analyte binding. These sensors typically rely on interferometry21, surface plasmon resonance22,23, photoluminescence24–27, or electrochemiluminescence18. These existing optical techniques are, however, less sensitive than mass spectrometry13–15,21–24 and require multiple steps which can increase user error. High-sensitivity single molecule optical biosensors have previously been demonstrated using optical microspheres coupled to plasmonic nanoparticles28,29, but the effective active area of these sensors is very small, limited to just the locations of the plasmonic hot spots on the nanoparticles. In addition, these hybrid whispering gallery mode plasmonic sensors suffer from inconsistent signal amplification due to variations in size of the plasmonic particles. Whispering gallery mode microtoroid optical resonators have also been used to sense temperature changes30 and particles in air31.
Here, we report for the first time the use of a label-free optical biosensing scheme known as FLOWER (frequency locked optical whispering evanescent resonator)32 to detect hCG in urine at a concentration as low as one femtomolar. This value is three orders of magnitude better than the capabilities of mass spectrometry. While we have previously reported using FLOWER to sense single macromolecules, this is the first demonstration of FLOWER for biodetection from human derived samples.
FLOWER uses optical whispering gallery mode technology in combination with electronic feedback control and data processing techniques to improve its signal-to-noise ratio. This enables thousands of times greater particle capture area than is provided by plasmonic particles, thus increasing the likelihood of detectable particle binding events. In general, optical microcavities such as microtoroids exhibit high detection sensitivity due to their long (on the order of tens of nanoseconds) photon confinement times. Each time light circulates the periphery of the resonator, it re-interrogates a bound analyte (Fig. 1b), causing large signal amplification. Particle binding events are detected by changes in the resonance frequency of the resonator due to changes in the refractive index within the evanescent field of the sensor. Functionalization of the sensor’s surface using capture agents such as antibodies enables selective detection.
In standard biological sensing experiments using optical microcavities, changes in resonance frequency of the optical microcavity are tracked by continuously scanning the wavelength of a tunable laser. FLOWER is different in that it adaptively tracks the resonance frequency of the resonator as particles bind, enabling ultra-high sensitivity without requiring comparatively slow spectral scanning. Data acquisition rates on the order of several hundred kHz are possible, allowing the detection of fast events such as single particle binding32 (Fig. 1c, see Methodology for details).
Methodology
Microtoroid fabrication.
Microtoroids were fabricated as previously described.33 Briefly, circular pads of photoresist were patterned on silicon wafers with a 2 μm thick thermal oxide layer. The areas that were not protected by the photoresist were removed using a weak hydrofluoric acid etch. Silicon pillars were selectively dry etched using XeF2, creating a microdisk structure. Afterwards, these structures were reflowed using a CO2 laser. Light from a ~780 nm tunable laser was evanescently coupled into the microtoroids using a tapered optical fiber. The quality factors (Q) of the microtoroids were measured before each experiment. As higher Q-factors provide better limits of detection, only toroids with Q-values higher than 107 were used for these experiments. A Q of 107 can be reliably obtained whereas an order of magnitude higher in Q (108) is more rare. Typically, we achieve Q-factors on chip which range from 105–108.
Microtoroid functionalization.
Microtoroids were functionalized immediately after the CO2 laser reflow process. Toroids were first incubated with a custom synthesized silane-PEG-maleimide linker solution for 30 min.32 After linker incubation, the chips were rinsed with ultrapure water, and soaked in a 5 μg/ml solution of mouse monoclonal anti-hCG IgG antibody in Phosphate Buffered Saline (PBS) for 5 minutes. After another rinse with ultrapure water, the samples were mounted on the measurement stage using cyanoacrylate glue. The antibody-coated microtoroid was continually immersed in 100 μl of simulated urine (Carolina Biological Supply Company). According to the supplier’s specifications, simulated urine is composed of 92.33% water, 7.64% glycerol, and 0.03% sodium hydroxide.
Experimental procedure.
A microaquarium was formed by gluing a glass coverslip to a glass spacer which was glued to the surface of our sample stage. The coverslips were pre-cleaned with 2-propanol and ultrapure water. All dilutions of hCG were prepared using simulated urine, except in the case of the bare microtoroid experiments, where sample dilutions were prepared using PBS. The laser frequency was locked to a resonance of microtoroid optical microcavity using a Toptica Digilock 110 frequency locking system, as previously described34. Cavity resonances were locked using a 2 kHz sinusoidal dither signal with a modulation amplitude of 15 mV. This corresponds to a dithering of 300 fm. Proportional-Integral-Derivative (PID) parameters were on the order of 10, 100, and 1, respectively, while an overall system gain on the order of 1000 was used. These parameters were slightly tuned in different experiments to obtain best results. Tuning was performed by applying a 0.1 V square voltage pulse at 0.5 Hz frequency to modulate the wavelength and observing successful tracking of wavelength shifts. Data was recorded using a 24-bit data acquisition card. Concentration dependent data is obtained by directly increasing the analyte concentration without a washing step. The infusion of the analyte was performed using a peristaltic pump operating at a rate of 10 μl/s. The sample chamber volume is approximately 100 μl. The sample chamber was flushed with 300 μl of analyte containing solution to ensure that the fluid in the sample chamber has been completely exchanged. There is no separate rinsing step following exposure to analyte as this would increase experimental complexity and was not found to mitigate non-specific binding. After waiting for 30 s for fluid-driven fluctuations of the optical fiber to stop, the resonant wavelength is tracked. Data was recorded with an acquisition rate of 10 kHz. The silicone tubing used to inject analyte solutions was cleaned with 0.1 M HCl and subsequent diH2O infusion before each experiment.
Data analysis.
Data was analysed using a custom MATLAB script. Resonant shifts were tracked over 20 seconds, which is long enough such that transients due to temperature and fiber taper fluctuations are less significant than binding-induced shifts, while keeping the total experiment time as short as possible, which is important for future high-throughput screening applications. After converting from voltage to wavelength (Fig. S2a), data was first Fourier filtered to remove 60 Hz electronic line noise and other periodic noise. (Fig. S2b and S2c). Then, a median filter of 1000 points was applied to smooth the data (Fig. S2d). The background noise level is measured as 0.0217 +/− 0.0069 fm at 1 s, and 0.0002 +/− 0.0001 fm at 1 ms, after Fourier and median filtering. The thermal drift was removed by subtracting a straight line corresponding to the initial slope of the filtered signal, since the thermal drifts in the relatively short measurement interval can be considered as linear. This assumption was verified by simultaneous temperature and wavelength shift measurements (Fig. S3 and Fig. S4).
Pregnancy test strip hCG concentration measurement.
Purified hCG, real urine samples obtained from pregnant donors at different trimesters of pregnancy, and control urine samples were each diluted in simulated urine. These samples were obtained commercially from Lee Biosolutions. Samples were diluted by factors of 102–106 to prevent saturation of the commercial test strips, which were used to quantify the amount of hCG from the pregnant donor samples. The images of test strips were collected using a smartphone camera under identical illumination conditions. The images were separated into their colour channels using ImageJ software and the green channel was used for analysis. After the selected channel was converted to grayscale and inverted, the average intensity from test line (T), control line (C), and background (B) were measured. The test line contrast is represented as:
Temperature measurements.
For measuring the correlation between temperature and resonance wavelength shifts of the microtoroid, a PID temperature controller was used to heat the sample stage. The temperature was simultaneously measured using a thermocouple. The cooling of the microtoroid was monitored within the time scale of the optical measurement and compared with the associated wavelength shift (Fig. S3). The data acquisition rate in thermal measurements was 1 Hz.
Results and Discussion
Limit of Detection of FLOWER for hCG
To determine the sensitivity of FLOWER for hCG detection, we measured the resonance frequency shifts associated with flowing different concentrations of hCG ranging from 100 aM to 10 nM over the toroid’s surface (Fig. 2a). The same microtoroid was used for each curve in this dilution series. These experiments were repeated using two additional toroids (Fig. 2b). For selectivity purposes, experiments were performed using a microtoroid functionalized with monoclonal antibodies for hCG. Simulated urine, which is a mixture of water, glycerol, and sodium hydroxide and has the same pH as urine35, was used to dilute the samples. The results demonstrate that our sensor can detect hCG over a 6 order of magnitude concentration range. The limit of detection was calculated to be 120 aM using the three-sigma method, which equals three times the standard deviation (σ) of repeated blank infusion experiments. The limit of quantification36 which determines how well one can distinguish between two separate concentrations is defined as 10σ and is calculated here to be 400 aM. The lowest experimentally-detected concentration we measured in our experiments was 1 fM. A control experiment using anti-amyloid-β to which hCG is not expected to bind was also performed. In this case, no concentration dependent increase in binding was observed (Figure 2c). The individual binding curves for Fig. 2a are shown in Fig 2d.
We note that in these experiments, the binding response includes both a contribution from temperature as well as a hCG binding. In contrast, in single particle binding experiments32, temperature drift occurs on a different time scale than particle binding. In addition, for single particle experiments, PID parameters were optimized for fast and small events. For the experiments in the current paper, which involve many molecules, the PID parameters are optimized to obtain a smooth curve without steps and the temperature drift is controlled by subtracting its contribution to the shift (Fig S4).
Measurement of hCG Levels in Urine
Using the calibration curve created from known concentrations of hCG spiked in simulated urine (Fig. 2), we used FLOWER to measure the concentration of hCG in real urine samples. As we did not have access to urine from athletes who dope with hCG, we instead measured the urine hCG levels obtained from pregnant women at different trimesters of pregnancy. As shown in Figure 3, we are able to detect hCG concentrations as low as 3 fM in human samples (Fig. 3b) diluted in simulated urine by a factor of 106. As control experiments, samples obtained from male and non-pregnant female urine samples were also diluted and measured. There was no detectable concentration dependence in the rate of resonance wavelength shift at dilutions of 104 and 106 (Fig. 3e and 3f). This agrees with our expectations, as undiluted male and non-pregnant female urine typically contain approximately 120 and 150 fM hCG37, respectively, and therefore, after dilution levels of 104 or 106, these concentrations would be below our detection threshold. Dilution also affects the concentrations of the other constituents in the urine and therefore also impacts nonspecific binding. For further validation, we also compared our FLOWER measurements of hCG to those of commercial pregnancy test strips (Fig. 3d and Fig. S1). The contrast of the test strip lines was calibrated with experiments performed using pregnancy test strips with known concentrations of hCG spiked into simulated urine (See Methods for details). Using the test strips, the hCG concentration for each trimester was measured to be 37 nM, 3 nM, and 11 nM, respectively. These values agreed well with our FLOWER measurements (Fig. 3d) and are within the reported range for hCG values during each trimester of pregnancy38,39; In addition, the relative amounts of hCG for each trimester are consistent with reported literature values, which indicate that hCG concentration is highest during the first trimester, is reduced tenfold during the second trimester, and reaches one half or one third the value of the first trimester during the third trimester.
Conclusions
We have demonstrated the detection of hCG in urine at a concentration of 1 fM in simulated urine and 3 fM in real urine samples. Our approach can provide high signal-to-noise ratio measurements over a large dynamic range. Figure 4 shows the limit of detection and the actual detection range of FLOWER in comparison with other hCG detection techniques, including mass spectrometry, which is the current gold standard. As shown in Figure 4, there is only one other technique, electrochemiluminescence18, that claims a lower 3σ limit of detection; however, the actual lowest concentration measured in that study is still higher than what FLOWER can measure. In addition, FLOWER possesses a greater dynamic range. Furthermore, FLOWER does not require labeling of the target molecule, thus eliminating the need for fluorescent or radioactive tags which increase assay complexity and cost. With FLOWER, there is no need to vaporize samples as is done in gas chromatography mass spectrometry (GC-MS) and there is no need to pre-concentrate samples. For doping tests, as urine composition will be different for everyone, we would measure a baseline response from each athlete and use that value as a reference. In the future, we will employ alternative light coupling strategies so that a tapered optical fiber no longer needs to be used and these devices can be eventually manufactured and maintained at a user facility. As one example, we have recently demonstrated through simulation that nanoantennas can be used for robust free-space coupling of light into and out of these cavities.40
In conclusion, we have demonstrated a label-free method that has the potential to be widely used in doping detection. We anticipate that FLOWER has outstanding potential for preventing unethical conduct in sports by reducing false positives and negatives and by making tighter doping regulations enforceable.
Supplementary Material
Acknowledgements
This work was supported by the Partnership for Clean Competition Grant No. 2016R2000218G. The authors thank J. N. Wycoff for assistance in data collection.
Footnotes
Associated Content
Supplementary figures and additional results and discussion (PDF).
Competing Interests
J.S. owns a financial interest in Femtoray Technologies which specializes in molecular label-free sensors.
References
- (1).Butch AW; Woldemariam GA Drug Test. Anal 2016, 8, 1147–1151. [DOI] [PubMed] [Google Scholar]
- (2).Butch AW; D AB; Avliyakulov NK Drug Test. Anal 2017. [DOI] [PubMed] [Google Scholar]
- (3).Thevis M; Thomas A; Schanzer W Anal. Bioanal. Chem 2011, 401, 405–420. [DOI] [PubMed] [Google Scholar]
- (4).Krone N; Hughes BA; Lavery GG; Stewart PM; Arlt W; Shackleton CH The Journal of steroid biochemistry and molecular biology 2010, 121, 496–504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (5).Butch AW; D AB; Avliyakulov NK Drug Test. Anal 2017. [DOI] [PubMed] [Google Scholar]
- (6).Gundry RL; White MY; Murray CI; Kane LA; Fu Q; Stanley BA; Van Eyk JE Current protocols in molecular biology 2009, Chapter 10, Unit10 25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (7).Giansanti P; Tsiatsiani L; Low TY; Heck AJR Nat. Protoc 2016, 11, 993–1006. [DOI] [PubMed] [Google Scholar]
- (8).Woldemariam GA; Butch AW Clin. Chem 2014, 60, 1089–1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (9).Thevis M; Kuuranne T; Geyer H Drug Test Anal 2018, 10, 9–27. [DOI] [PubMed] [Google Scholar]
- (10).van den Broek I; Blokland M; Nessen MA; Sterk S Mass Spectrom. Rev 2015, 34, 571–594. [DOI] [PubMed] [Google Scholar]
- (11).Fan J; Wang M; Wang CY; Cao Y Bioanalysis 2017, 9, 1509–1529. [DOI] [PubMed] [Google Scholar]
- (12).Yang HC; Yuan R; Chai YQ; Su HL; Zhuo Y; Jiang W; Song ZJ Electrochim. Acta 2011, 56, 1973–1980. [Google Scholar]
- (13).Sanchez S; Roldan M; Perez S; Fabregas E Anal. Chem 2008, 80, 6508–6514. [DOI] [PubMed] [Google Scholar]
- (14).Teixeira S; Burwell G; Castaing A; Gonzalez D; Conlan RS; Guy OJ Sens. Actuator B-Chem 2014, 190, 723–729. [Google Scholar]
- (15).Xia N; Chen ZH; Liu YD; Ren HZ; Liu L Sens. Actuator B-Chem 2017, 243, 784–791. [Google Scholar]
- (16).Yang L; Zhao H; Fan SM; Deng SS; Lv Q; Lin J; Li CP Biosens. Bioelectron 2014, 57, 199–206. [DOI] [PubMed] [Google Scholar]
- (17).Lu JJ; Liu SQ; Ge SG; Yan M; Yu JH; Hu XT Biosens. Bioelectron 2012, 33, 29–35. [DOI] [PubMed] [Google Scholar]
- (18).Zhang A; Guo WW; Ke H; Zhang X; Zhang H; Huang CS; Yang DP; Jia NQ; Cui DX Biosens. Bioelectron 2018, 101, 219–226. [DOI] [PubMed] [Google Scholar]
- (19).Yang H; Yuan R; Chai Y; Zhuo Y Colloids and surfaces. B, Biointerfaces 2011, 82, 463–469. [DOI] [PubMed] [Google Scholar]
- (20).Stulik K Electroanal 1999, 11, 1001–1004. [Google Scholar]
- (21).Schneider BH; Edwards JG; Hartman NF Clin. Chem 1997, 43, 1757–1763. [PubMed] [Google Scholar]
- (22).Boozer C; Yu QM; Chen SF; Lee CY; Homola J; Yee SS; Jiang SY Sens. Actuator B-Chem 2003, 90, 22–30. [Google Scholar]
- (23).Dostalek J; Ctyroky J; Homola J; Brynda E; Skalsky M; Nekvindova P; Spirkova J; Skvor J; Schrofel J Sens. Actuator B-Chem 2001, 76, 8–12. [Google Scholar]
- (24).Yan X; Huang ZB; He M; Liao XM; Zhang CQ; Yin GF; Gu JW Colloid Surf. B-Biointerfaces 2012, 89, 86–92. [DOI] [PubMed] [Google Scholar]
- (25).Zhou CH; Yuan H; Shen HB; Guo Y; Li XM; Liu D; Xu L; Ma L; Li LS J. Mater. Chem 2011, 21, 7393–7400. [Google Scholar]
- (26).Wang WG; Zou YK; Yan JW; Liu J; Chen HX; Li S; Zhang L Spectroc. Acta Pt. A-Molec. Biomolec. Spectr 2018, 193, 102–108. [DOI] [PubMed] [Google Scholar]
- (27).Kuo HT; Yeh JZ; Jiang CM; Wu MC J. Immunol. Methods 2012, 381, 32–40. [DOI] [PubMed] [Google Scholar]
- (28).Baaske MD; Foreman MR; Vollmer F Nat. Nanotechnol 2014, 9, 933–939. [DOI] [PubMed] [Google Scholar]
- (29).Kim E; Baaske MD; Schuldes I; Wilsch PS; Vollmer F Science advances 2017, 3, e1603044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (30).Xu X; Chen W; Zhao G; Li Y; Lu C; Yang L Light, science & applications 2018, 7, 62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (31).Zhu J; Ozdemir SK; Xiao Y-F; Li L; He L; Chen D-R; Yang L Nature Photonics 2009, 4, 46. [Google Scholar]
- (32).Su J; Goldberg AFG; Stoltz BM Light Sci. Appl 2016, 5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (33).Armani DK; Kippenberg TJ; Spillane SM; Vahala KJ Nature 2003, 421, 925–928. [DOI] [PubMed] [Google Scholar]
- (34).Su J ACS Photonics 2015, 2, 1241–1245. [Google Scholar]
- (35).Hamorsky KT; Ensor CM; Pasini P; Daunert S Anal. Biochem 2012, 421, 172–180. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (36).Anal. Chem 1980, 52, 2242–2249. [Google Scholar]
- (37).Stenman UH; Alfthan H; Ranta T; Vartiainen E; Jalkanen J; Seppala MJ Clin. Endocrinol. Metab 1987, 64, 730–736. [DOI] [PubMed] [Google Scholar]
- (38).MacGregor WG; Gale CW; Simmons E; Knight GJ J. Obstet. Gynaec. Brit. Cwlth 1966, 73, 775–782. [DOI] [PubMed] [Google Scholar]
- (39).Faiman C; Ryan RJ; Zwirek SJ; Rubin ME J. Clin. Endocrinol. Metab 1968, 28, 1323–1329. [DOI] [PubMed] [Google Scholar]
- (40).Chen L, Li C, Su J, McLeod E Photonics Research 2019, 7, 967–976. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.